Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial
Titel:
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial
Auteur:
Ladenstein, Ruth Pötschger, Ulrike Valteau-Couanet, Dominique Luksch, Roberto Castel, Victoria Yaniv, Isaac Laureys, Genevieve Brock, Penelope Michon, Jean Marie Owens, Cormac Trahair, Toby Chan, Godfrey Chi Fung Ruud, Ellen Schroeder, Henrik Beck Popovic, Maja Schreier, Guenter Loibner, Hans Ambros, Peter Holmes, Keith Castellani, Maria Rita Gaze, Mark N Garaventa, Alberto Pearson, Andrew D J Lode, Holger N